Supplementary material

Supplementary table 1: PBMC genes from obese boys repressed or overexpressed in the LR group compared with the HR group at baseline (A) and the genes downregulated or upregulated in the HR group after the moderate calorie-restriction (B).

A)

| Gene symbol | Accesion code | Description | Biological process | | FDR | FC |
|--------------|-----------------|---|---|-------|-------|--------|
| IGKC | BC073772 | Immunoglobulin kappa constant | Immune response | | 0.363 | -1.753 |
| IGKC | AF113887 | Immunoglobulin kappa constant | Immune response | | 0.513 | -1.641 |
| HLA-DRB3 | NM_022555 | Major histocompatibility complex, class II, DR beta 3 | Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 0.017 | 0.463 | -1.590 |
| LOC652493 | ENST00000390249 | NA | Biological process unclassified | 0.035 | 0.544 | -1.545 |
| APOBEC3B | NM_004900 | Apolipoprotein B mRNA editing enzyme, catalytic polypeptide | Biological process unclassified | 0.022 | 0.499 | -1.542 |
| IGKC | ENST00000390273 | Immunoglobulin kappa constant | Immune response | 0.013 | 0.437 | -1.525 |
| LOC100291056 | ENST00000390631 | NA | Biological process unclassified | 0.019 | 0.471 | -1.518 |
| ELOVL7 | NM_024930 | ELOVL family member 7, elongation of long chain fatty acids | Fatty acid biosynthetic process | 0.022 | 0.504 | 1.500 |
| PCSK6 | NM_002570 | Proprotein convertase subtilisin | Glycoprotein metabolic process | 0.003 | 0.286 | 1.501 |
| LEPR | NM_002303 | Leptin receptor | Angiogenesis | 0.004 | 0.304 | 1.502 |
| CTDSPL | NM_001008392 | CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A | Biological process unclassified | 0.006 | 0.363 | 1.504 |
| ME1 | NM_002395 | Malic enzyme 1, NADP(+)-dependent, cytosolic | Carbohydrate metabolic process | 0.009 | 0.406 | 1.511 |
| EGF | NM_001963 | Epidermal growth factor | Activation of MAPKK activity | 0.017 | 0.463 | 1.518 |
| ITGB5 | NM_002213 | Integrin, beta 5 | Muscle contraction | 0.000 | 0.152 | 1.518 |
| EPB49 | NM_001978 | Erythrocyte membrane protein band 4.9 (dematin) | Cytoskeleton organization | 0.000 | 0.161 | 1.521 |
| PBX1 | NM_002585 | Pre-B-cell leukemia homeobox 1 | Urogenital system development | 0.008 | 0.379 | 1.521 |
| GPR34 | NM_001097579 | G protein-coupled receptor 34 | Intracellular protein transport | 0.013 | 0.437 | 1.523 |
| WASF3 | NM_006646 | WAS protein family, member 3 | Protein complex assembly | 0.019 | 0.471 | 1.530 |
| PDZK1IP1 | NM_005764 | PDZK1 interacting protein 1 | Biological process unclassified | 0.045 | 0.568 | 1.530 |
| MARCH2 | NM_016496 | Membrane-associated ring finger (C3HC4) 2 | Endocytosis | 0.001 | 0.176 | 1.535 |
| VIL1 | NM_007127 | Villin 1 | Protein complex assembly | 0.001 | 0.217 | 1.536 |
| CD8B | NM_172099 | CD8b molecule | Immune response | 0.010 | 0.420 | 1.541 |
| SLC6A4 | NM_001045 | Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | Neurotransmitter uptake | 0.007 | 0.368 | 1.545 |
| MFSD1 | NM_022736 | Major facilitator superfamily domain containing 1 | Transmembrane transport | 0.002 | 0.220 | 1.551 |
| ASAP2 | NM_003887 | ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 | Regulation of ARFGTPase activity | 0.000 | 0.081 | 1.565 |
| LIPH | NM_139248 | Lipase, member H | Lipid catabolic process | 0.014 | 0.447 | 1.572 |
| ALOX12 | NM_000697 | Arachidonate 12-lipoxygenase | Oxygen and reactive oxygen species metabolic process | 0.015 | 0.451 | 1.585 |
| ITGB3 | NM_000212 | Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61 | Cell-substrate junction assembly | 0.001 | 0.161 | 1.594 |
| MPL | NM_005373 | Myeloproliferative leukemia virus oncogene | Cell surface receptor linked signaling pathway | 0.007 | 0.367 | 1.595 |
| SH3BGRL2 | NM_031469 | SH3 domain binding glutamic acid-rich protein like 2 | Biological process unclassified | 0.003 | 0.263 | 1.597 |

| 1 | 1 | | | 1 | 1 1 | 1 1 |
|----------|-----------|--|---|-------|-------|-------|
| ENKUR | NM_145010 | Enkurin, TRPC channel interacting protein | Biological process unclassified | | 0.324 | 1.617 |
| THBS1 | NM_003246 | Thrombospondin 1 | Activation of MAPK activity | | 0.437 | 1.622 |
| GUCY1B3 | NM_000857 | Guanylate cyclase 1, soluble, beta 3 | cGMP biosynthetic process | 0.002 | 0.222 | 1.626 |
| DNM3 | NM_015569 | Dynamin 3 | Endocytosis | 0.000 | 0.161 | 1.630 |
| CALD1 | NM_033138 | Caldesmon 1 | Cellular component movement | 0.006 | 0.352 | 1.634 |
| GP1BA | NM_000173 | Glycoprotein lb (platelet), alpha polypeptide | Cell adhesion | 0.000 | 0.137 | 1.647 |
| PDE3A | NM_000921 | Phosphodiesterase 3A, cGMP-inhibited | Oocyte maturation | 0.003 | 0.267 | 1.652 |
| FSTL1 | NM_007085 | Follistatin-like 1 | BMP signaling pathway | 0.014 | 0.450 | 1.665 |
| ENDOD1 | NM_015036 | Endonuclease domain containing 1 | Biological process unclassified | 0.002 | 0.217 | 1.666 |
| CTTN | NM_005231 | Cortactin | Biological process unclassified | 0.008 | 0.379 | 1.688 |
| LTBP1 | NM_206943 | Latent transforming growth factor beta binding protein 1 | Biological process unclassified | 0.001 | 0.161 | 1.693 |
| CLEC1B | NM_016509 | C-type lectin domain family 1, member B | Defense response | 0.009 | 0.392 | 1.699 |
| ITGA2B | NM_000419 | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa, antigen CD41) | Cell adhesion | 0.003 | 0.274 | 1.705 |
| PRKAR2B | NM_002736 | Protein kinase, cAMP-dependent, regulatory, type II, beta | Regulation of protein amino acid phosphorylation | 0.001 | 0.161 | 1.718 |
| SNORA30 | NR_002966 | Small nucleolar RNA, H/ACA box 30 | Biological process unclassified | 0.000 | 0.137 | 1.749 |
| PVALB | NM_002854 | Parvalbumin | Biological process unclassified | 0.017 | 0.463 | 1.780 |
| SELP | NM_003005 | Selectin P (granule membrane protein 140kDa, antigen CD62) | Regulation of cellular extravasation | 0.001 | 0.161 | 1.817 |
| TFPI | NM_006287 | Tissue factor pathway inhibitor | Blood coagulation | 0.000 | 0.152 | 1.817 |
| MMRN1 | NM_007351 | Multimerin 1 | Cell adhesion | 0.000 | 0.137 | 1.835 |
| PKHD1L1 | NM_177531 | Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 | Biological process unclassified | 0.000 | 0.081 | 1.871 |
| GSTM4 | NM_000850 | Glutathione S-transferase mu 4 | Metabolic process | 0.036 | 0.544 | 1.911 |
| JAM3 | NM_032801 | Junctional adhesion molecule 3 | Biological process unclassified | 0.004 | 0.307 | 2.091 |
| LGALS2 | NM_006498 | Lectin, galactoside-binding, soluble, 2 | Biological process unclassified | 0.012 | 0.434 | 2.378 |
| HLA-DPB1 | NM_002121 | Major histocompatibility complex, class II, DP beta 1 | Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 0.041 | 0.548 | 2.441 |
| SIRPB1 | NM_006065 | Signal-regulatory protein beta 1 | Signal transduction | 0.000 | 0.001 | 4.087 |

Transcript with ± 1.5 -FC and p-value<0.05 were considered significant. FDR: false discovery rate; FC: fold-change; NA: not available. The genes selected for validation with QPCR appear with their gene symbol in bold and their rows highlighted in grey.

| Gene symbol | Accesion code | Description | Biological process | | FDR | FC |
|-------------|---------------|---|---|-------|-------|--------|
| AREG | NM_001657 | Amphiregulin | Epidermal growth factor receptor signaling pathway | | 0.286 | -3.215 |
| HBEGF | NM_001945 | Heparin-binding EGF-like growth factor | Signal transduction | | 0.336 | -2.544 |
| NR4A2 | NM_006186 | Nuclear receptor subfamily 4, group A, member 2 | Response to hypoxia | 0.001 | 0.255 | -2.490 |
| NR4A3 | NM_006981 | Nuclear receptor subfamily 4, group A, member 3 | Mesoderm formation | 0.004 | 0.301 | -2.468 |
| CSNK1D | NM_001893 | Casein kinase 1, delta | DNA repair | 0.019 | 0.371 | -2.415 |
| RGS1 | NM_002922 | Regulator of G-protein signaling 1 | Immune response | 0.001 | 0.255 | -2.216 |
| TNFAIP3 | NM_006290 | Tumor necrosis factor, alpha-induced protein 3 | Apoptosis | 0.002 | 0.286 | -2.135 |
| GRASP | NM_181711 | GRP1 (general receptor for phosphoinositides 1)-associated | Signal transduction | 0.003 | 0.299 | -2.050 |
| MOP-1 | AB014771 | NA | Biological process unclassified | 0.022 | 0.371 | -2.021 |
| SIK1 | NM_173354 | Salt-inducible kinase 1 | Negative regulation of transcription from RNA polymerase II | 0.003 | 0.299 | -1.984 |
| RASGEF1B | NM_152545 | RasGEF domain family, member 1B | Regulation of small GTPase mediated signal transduction | 0.034 | 0.386 | -1.946 |
| MIR221 | NR_029635 | MicroRNA 221 | Biological process unclassified | 0.020 | 0.371 | -1.898 |
| NR4A1 | NM_002135 | Nuclear receptor subfamily 4, group A, member 1 | Regulation of transcription, DNA-dependent | 0.004 | 0.333 | -1.865 |
| CD83 | NM_004233 | CD83 molecule | Defense response | 0.026 | 0.375 | -1.859 |
| CD69 | NM_001781 | CD69 molecule | Biological process unclassified | 0.013 | 0.371 | -1.859 |
| EREG | NM_001432 | Epiregulin | Angiogenesis | 0.000 | 0.232 | -1.753 |
| PER1 | NM_002616 | Period homolog 1 (Drosophila) | Regulation of transcription, DNA-dependent | 0.002 | 0.286 | -1.740 |
| CCL3L1 | NM_021006 | Chemokine (C-C motif) ligand 3-like 1 | Chemotaxis | 0.028 | 0.376 | -1.693 |
| DUSP2 | NM_004418 | Dual specificity phosphatase 2 | Inactivation of MAPK activity | 0.028 | 0.375 | -1.691 |
| PPP1R15A | NM_014330 | Protein phosphatase 1, regulatory (inhibitor) subunit 1 | Regulation of translation | 0.032 | 0.383 | -1.665 |
| NFKBIA | NM_020529 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | Protein import into nucleus, translocation | 0.011 | 0.371 | -1.665 |
| JUN | NM_002228 | Jun oncogene | Angiogenesis | 0.016 | 0.371 | -1.664 |
| ZC3H12A | NM_025079 | Zinc finger CCCH-type containing 12A | Angiogenesis | 0.016 | 0.371 | -1.637 |
| FOSL1 | NM_005438 | FOS-like antigen 1 | Regulation of transcription from RNA polymerase II promoter | 0.043 | 0.393 | -1.620 |
| FLJ14107 | NR_027715 | Hypothetical LOC80094 | Biological process unclassified | 0.030 | 0.379 | -1.610 |
| NFKBID | NM_139239 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, delta | Inflammatory response | 0.020 | 0.371 | -1.600 |
| PFKFB3 | NM_004566 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 | Fructose 2,6-bisphosphate metabolic process | 0.024 | 0.371 | -1.575 |
| LRRFIP1 | NM_001137550 | Leucine rich repeat (in FLII) interacting protein 1 | Regulation of transcription from RNA polymerase II | 0.048 | 0.399 | -1.550 |
| DDIT4 | NM_019058 | DNA-damage-inducible transcript 4 | Response to hypoxia | 0.008 | 0.368 | -1.541 |
| FAM46C | NM_017709 | Family with sequence similarity 46, member C | Biological process unclassified | 0.005 | 0.346 | -1.526 |
| DUSP8 | NM_004420 | Dual specificity phosphatase 8 | Inactivation of MAPK activity | 0.048 | 0.399 | -1.522 |
| OSM | NM_020530 | Oncostatin M | Positive regulation of acute inflammatory response | 0.030 | 0.381 | -1.520 |

| PLK3 | NM_004073 | Polo-like kinase 3 (Drosophila) | Protein amino acid phosphorylation | 0.044 | 0.393 | -1.516 |
|--------------|--------------|---|---|-------|-------|--------|
| BTLA | NM_181780 | B and T lymphocyte associated | Immune response-regulating cell surface receptor signalling pathway | 0.017 | 0.371 | 1.510 |
| BBS10 | NM_024685 | Bardet-Biedl syndrome 10 | Retina homeostasis | 0.009 | 0.371 | 1.523 |
| LOC100128751 | AY194294 | NA | Biological process unclassified | 0.044 | 0.393 | 1.532 |
| CD180 | NM_005582 | CD180 molecule | Inflammatory response | 0.007 | 0.348 | 1.555 |
| FANCF | NM_022725 | Fanconi anemia, complementation group F | DNA repair | 0.013 | 0.371 | 1.557 |
| GIMAP4 | NM_018326 | GTPase, IMAP family member 4 | Biological process unclassified | 0.047 | 0.399 | 1.586 |
| C8orf44 | NM_019607 | Chromosome 8 open reading frame 44 | Protein amino acid phosphorylation | 0.010 | 0.371 | 1.589 |
| GIMAP8 | NM_175571 | GTPase, IMAP family member 8 | Biological process unclassified | 0.006 | 0.348 | 1.670 |
| ZNF780B | NM_001005851 | Zinc finger protein 780B | Regulation of transcription, DNA-dependent | 0.010 | 0.371 | 1.789 |

 $Transcript \quad with \quad \pm 1.5 \text{-FC} \quad and \quad p-value < 0.05 \quad were \quad considered \quad significant. \quad FDR: \quad false \quad discovery \quad rate; \quad FC: \quad fold-change; \quad NA: \quad not \quad available.$

Supplementary table 2: Gene analysis as classified by Gene Ontology (GO), biological processes, that were significantly different between high and low responders at baseline. FE: Fold Enrichment.

| GO Categories | Number of Genes | p-value | (FE) |
|---|-----------------|----------|------|
| Platelet activation | 8 | 1.60E-04 | 6.6 |
| JAK-STAT cascade | 7 | 3.30E-03 | 4.7 |
| Unsaturated fatty acid biosynthetic process | 5 | 3.90E-02 | 3.9 |
| Blood coagulation | 14 | 1.30E-04 | 3.6 |
| Regulation of blood coagulation | 5 | 4.70E-02 | 3.6 |
| Haemostasis | 14 | 2.30E-04 | 3.4 |
| Fatty acid biosynthetic process | 9 | 1.00E-02 | 3.0 |
| Regulation of body fluid levels | 14 | 2.80E-03 | 2.6 |
| Regulation of homeostatic process | 11 | 1.20E-02 | 2.5 |
| Regulation of I-kappaB kinase/NF-kappaB cascade | 10 | 2.10E-02 | 2.5 |
| Homeostasis of number of cells | 9 | 3.70E-02 | 2.4 |
| Chromatin assembly | 8 | 4.80E-02 | 2.4 |
| Positive regulation of cell differentiation | 19 | 2.90E-03 | 2.2 |
| Negative regulation of programmed cell death | 28 | 6.00E-04 | 2.0 |
| Regulation of cell motion | 15 | 1.60E-02 | 2.0 |
| Intracellular transport | 41 | 2.30E-03 | 1.6 |
| Intracellular signalling cascade | 68 | 2.80E-03 | 1.4 |
| Regulation of cell death | 44 | 1.80E-02 | 1.4 |
| Response to wounding | 29 | 4.80E-02 | 1.4 |

Supplementary table 3: Gene analysis as classified by Gene Ontology (GO), biological processes, that were significantly change by the nutritional intervention in high and low responder groups. FE: Fold Enrichment.

| GO Categories | High responders | | | Low responders | | |
|---|-----------------|----------|-----|----------------|----------|------|
| | Number of | <u> </u> | | Number of | · · | |
| | Genes | p-value | FE | Genes | p-value | FE |
| Angiogenesis | | | | 14 | 4.00E-02 | 1.8 |
| Cellular response to stress | 42 | 1.30E-02 | 1.5 | 41 | 2.20E-02 | 1.4 |
| Cytoplasmic sequestering of NF-kappa | | | | 3 | 2.40E-02 | 11.6 |
| Defence response | | | | 42 | 4.50E-02 | 1.3 |
| ER-nuclear signalling pathway | 6 | 3.20E-02 | 3.3 | | | |
| Glycerophospholipid biosynthetic process | 9 | 2.20E-02 | 2.6 | | | |
| I-kappaB kinase/NF-kappaB cascade | | | | 9 | 1.50E-02 | 2.8 |
| Immune response | | | | 65 | 3.90E-07 | 1.9 |
| IMP metabolic process | 3 | 3.40E-02 | 9.7 | | | |
| Inflammatory response | | | | 28 | 8.70E-03 | 1.7 |
| Leukocyte homeostasis | | | | 6 | 3.60E-02 | 3.2 |
| Lymphocyte differentiation | 11 | 3.80E-02 | 2.1 | | | |
| Lymphocyte homeostasis | 6 | 1.30E-02 | 4.2 | 6 | 1.30E-02 | 4.1 |
| Macromolecule catabolic process | 59 | 2.13E-03 | 1.5 | 55 | 1.30E-02 | 1.4 |
| Negative regulation of NF-kappaB import into nucleus | 3 | 4.60E-02 | 8.3 | 4 | 4.10E-03 | 11.1 |
| Negative regulation of transcription factor import into nucleus | | | | 5 | 4.60E-03 | 6.9 |
| Positive regulation of chemokine production | | | | 3 | 4.70E-02 | 8.3 |
| Positive regulation of defence response to virus by host | | | | 3 | 2.40E-02 | 11.6 |
| Positive regulation of epithelial to mesenchymal transition | 3 | 4.60E-02 | 8.3 | | | |
| Positive regulation of gene expression | | | | 41 | 3.60E-02 | 1.4 |
| Positive regulation of innate immune response | 7 | 2.90E-02 | 3.0 | | | |
| Positive regulation of lymphocyte activation | | | | 13 | 4.10E-03 | 2.6 |
| Positive regulation of nitrogen compound metabolic process | | | | 47 | 1.40E-02 | 1.4 |
| Regulation of cytokine production | 18 | 1.20E-02 | 1.9 | | | |
| Regulation of I-kappaB kinase/NF-kappaB cascade | | | | 11 | 4.90E-02 | 2.0 |
| Regulation of lymphocyte activation | | | | 17 | 3.80E-03 | 2.2 |
| Regulation of NF-kappaB import into nucleus | | | | 5 | 1.20E-02 | 5.4 |
| Regulation of nitric oxide biosynthetic process | | | | 5 | 4.80E-02 | 3.6 |
| Response to corticosterone stimulus | 4 | 4.60E-02 | 4.9 | | | |
| Response to protein stimulus | | | | 12 | 2.20E-02 | 2.2 |
| Response to unfolded protein | | | | 9 | 2.90E-02 | 2.5 |
| Response to virus | | | | 12 | 2.30E-02 | 2.2 |